Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
5 min read
diclofenac diethylamine: Detailed Review of its Transformative R&D Success
12 October 2023
This article summarized the latest R&D progress of diclofenac diethylamine, the Mechanism of Action for diclofenac diethylamine, and the drug target R&D trends for diclofenac diethylamine.
Latest Hotspot
3 min read
Caliway's CBL-514 demonstrated superior effectiveness compared to Liposuction
12 October 2023
Caliway Biopharmaceuticals announced successful primary and secondary endpoints of the phase 2 stage 2 trial for CBL-0202, outperforming placebo in ITT and PP groups.
Bio Sequence
2 min read
The Premier Instrument for Sequence Alignment: A Deeper Exploration
12 October 2023
EMBL-EBI offers a plethora of widely trusted online tools for sequence alignment. Moreover, our emphasis is laid on a profound recommendation: a user-friendly, commercial Patsnap Bio Sequence Database sequence alignment tool, which commendably offers free registration.
Latest Hotspot
3 min read
Rocket Pharmaceuticals reveals that FDA Acceptance of BLA for RP-L201
12 October 2023
The U.S. FDA has granted Priority Review to Rocket Pharmaceuticals, Inc. for their late-stage gene therapy, RP-L201 (marnetegragene autotemcel).
Drug Insights
4 min read
Exploring cabotegravir/rilpivirine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
12 October 2023
This article summarized the latest R&D progress of cabotegravir/rilpivirine, the Mechanism of Action for cabotegravir/rilpivirine, and the drug target R&D trends for cabotegravir/rilpivirine.
Latest Hotspot
3 min read
Lassen Therapeutics revealed preclinical findings related to LASN01, an Anti-IL-11 Receptor Antibody for Thyroid Eye Disease
12 October 2023
Presenting new preclinical data on LASN01 for treating TED, Lassen Therapeutics, a biotechnology firm engaged in clinical stages, is pioneering unique antibody therapeutics.
Valuable Targets
4 min read
Analysis on the Clinical Research Progress of Mineralocorticoid Receptor Antagonist
12 October 2023
The role of the MR (Mineralocorticoid Receptor) in the human body is crucial for maintaining electrolyte and fluid balance.
Latest Hotspot
3 min read
Kashiv BioSciences Administers First Patient in Phase III Clinical Trial for ADL018
12 October 2023
Kashiv BioSciences, LLC declared the start of enrollment for their Phase III clinical trial initiating with their first patient for their biosimilar candidate, ADL018, a potential alternative to XOLAIR®.
Drug Insights
5 min read
bupivacaine hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
12 October 2023
This article summarized the latest R&D progress of bupivacaine hydrochloride, the Mechanism of Action for bupivacaine hydrochloride, and the drug target R&D trends for bupivacaine hydrochloride.
Latest Hotspot
3 min read
Nexcella reveals clinical data from NXC-201 study in Multiple Myeloma
12 October 2023
Nexcella Inc. revealed updates from its ongoing Phase 1b/2 NEXICART-1 trial on its proprietary BCMA-targeted CAR T cell treatment, NXC-201.
Advanced Tech.
5 min read
Analysis on the Research Progress of Recombinant Protein
12 October 2023
Recombinant protein refers to the protein obtained using recombinant DNA or RNA technology.
Latest Hotspot
3 min read
A Phase III trial investigating Novartis' experimental drug, Iptacopan, displayed findings in IgAN patients
12 October 2023
Novartis reported promising initial results from a 9-month interim assessment of the Phase III APPLAUSE-IgAN trial. The experimental factor B inhibitor, iptacopan, showed superior effectiveness in reducing proteinuria compared to placebo.